Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients

M. Tomirotti; G. Bernardo; C. Epifani; R. Biasioli; R. Franchi; F. Mensi; P. Carnaghi; G. Schieppati; A. Scanni

Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients

M. Tomirotti, G. Bernardo, C. Epifani, R. Biasioli, R. Franchi, F. Mensi, P. Carnaghi, G. Schieppati, A. Scanni

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Thirty-one patients with metastatic breast cancer not responding or progressing after initial response to adriamycin + cyclophosphamide (AC) treatment entered a phase II study with oral lonidamine in association to AC. Objective clinical responses were observed in 10 patients (32%) and consisted of 1 complete + 9 partial remissions. Disease stability and progression were observed in 8 and 13 cases, respectively. These results were obtained with a marginal toxicity in addition to that already reported for AC therapy, the main additional side effect being myalgia, which was easily manageable in most cases.

Original language	English
Pages (from-to)	213-218
Number of pages	6
Journal	International Journal of Oncology
Volume	3
Issue number	2
Publication status	Published - 1993

ASJC Scopus subject areas

Cancer Research
Oncology

Fingerprint Dive into the research topics of 'Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients'. Together they form a unique fingerprint.

Cite this

Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients. / Tomirotti, M.; Bernardo, G.; Epifani, C.; Biasioli, R.; Franchi, R.; Mensi, F.; Carnaghi, P.; Schieppati, G.; Scanni, A.

In: International Journal of Oncology, Vol. 3, No. 2, 1993, p. 213-218.

Research output: Contribution to journal › Article › peer-review

@article{b2b496701ca54ba5bf6a3d68c7ce694c,

title = "Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients",

abstract = "Thirty-one patients with metastatic breast cancer not responding or progressing after initial response to adriamycin + cyclophosphamide (AC) treatment entered a phase II study with oral lonidamine in association to AC. Objective clinical responses were observed in 10 patients (32%) and consisted of 1 complete + 9 partial remissions. Disease stability and progression were observed in 8 and 13 cases, respectively. These results were obtained with a marginal toxicity in addition to that already reported for AC therapy, the main additional side effect being myalgia, which was easily manageable in most cases.",

author = "M. Tomirotti and G. Bernardo and C. Epifani and R. Biasioli and R. Franchi and F. Mensi and P. Carnaghi and G. Schieppati and A. Scanni",

year = "1993",

language = "English",

volume = "3",

pages = "213--218",

journal = "International Journal of Oncology",

issn = "1019-6439",

publisher = "Spandidos Publications",

number = "2",

}

TY - JOUR

T1 - Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients

AU - Tomirotti, M.

AU - Bernardo, G.

AU - Epifani, C.

AU - Biasioli, R.

AU - Franchi, R.

AU - Mensi, F.

AU - Carnaghi, P.

AU - Schieppati, G.

AU - Scanni, A.

PY - 1993

Y1 - 1993

N2 - Thirty-one patients with metastatic breast cancer not responding or progressing after initial response to adriamycin + cyclophosphamide (AC) treatment entered a phase II study with oral lonidamine in association to AC. Objective clinical responses were observed in 10 patients (32%) and consisted of 1 complete + 9 partial remissions. Disease stability and progression were observed in 8 and 13 cases, respectively. These results were obtained with a marginal toxicity in addition to that already reported for AC therapy, the main additional side effect being myalgia, which was easily manageable in most cases.

AB - Thirty-one patients with metastatic breast cancer not responding or progressing after initial response to adriamycin + cyclophosphamide (AC) treatment entered a phase II study with oral lonidamine in association to AC. Objective clinical responses were observed in 10 patients (32%) and consisted of 1 complete + 9 partial remissions. Disease stability and progression were observed in 8 and 13 cases, respectively. These results were obtained with a marginal toxicity in addition to that already reported for AC therapy, the main additional side effect being myalgia, which was easily manageable in most cases.

UR - http://www.scopus.com/inward/record.url?scp=0027272273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027272273&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027272273

VL - 3

SP - 213

EP - 218

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 2

ER -

Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients

Abstract

ASJC Scopus subject areas

Other files and links

Cite this